Retatrutide Research Peptide: The Triple-Agonist Data
Retatrutide is the first triple hormone receptor agonist to reach late-stage trials, activating GLP-1, GIP, and glucagon receptors in a single molecule. Semaglutide works on GLP-1 alone. Tirzepatide adds GIP. Retatrutide adds glucagon receptor activity on top of both, and that third mechanism is what separates its research profile from the other two. Why the […]